About Neurodegenerative Disease Research, Inc.
Funded research that directly benefits ALS patients
Neurodegenerative Disease Research, Inc. is a not-for-profit organization that was formed with a mission to fund researchers with an emphasis to identify and validate biomarkers for determining drug effectiveness in neurodegenerative diseases and facilitate pathology-based treatments to ALS patients. NDR supports open access to all findings via peer-reviewed publications.
NDR has funded projects to date include the following:
+ Identifying markers for stressed tissue from adipose-derived stem cells
+ Investigating immune checkpoint cell signaling, in vitro analysis of perivascular stem cell repair of cell damage
+ Evaluating cytokine responses of treated peripheral blood mononuclear cells
+ Studies using SOD1 mouse models of ALS
+ Evaluating the components of conditioned media from various sources
+ Development of secretome as an ALS treatment
+ Modification of therapeutic molecules to increase effectiveness and decrease toxicity in ALS patients
+ Use of DNA and RNA analyses that define ALS phenotypes and metabolomic studies including metabolomics and miRNA studies
+ Bringing the novel retro-inverso thymopentin, a neuroinflammatory modulator, into clinical trials